ATE223926T1 - Verfahren zur herstellung von igf-1 und igfbp-3 mit richtiger faltung und disulfidbindungen - Google Patents

Verfahren zur herstellung von igf-1 und igfbp-3 mit richtiger faltung und disulfidbindungen

Info

Publication number
ATE223926T1
ATE223926T1 AT96916829T AT96916829T ATE223926T1 AT E223926 T1 ATE223926 T1 AT E223926T1 AT 96916829 T AT96916829 T AT 96916829T AT 96916829 T AT96916829 T AT 96916829T AT E223926 T1 ATE223926 T1 AT E223926T1
Authority
AT
Austria
Prior art keywords
igfbp
igf
disulfide bonds
proper folding
cofolding
Prior art date
Application number
AT96916829T
Other languages
English (en)
Inventor
Andreas Sommer
Yasushi Ogawa
Peggy Tao
Original Assignee
Celtrix Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celtrix Pharma filed Critical Celtrix Pharma
Application granted granted Critical
Publication of ATE223926T1 publication Critical patent/ATE223926T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4743—Insulin-like growth factor binding protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compounds Of Unknown Constitution (AREA)
AT96916829T 1995-06-07 1996-05-30 Verfahren zur herstellung von igf-1 und igfbp-3 mit richtiger faltung und disulfidbindungen ATE223926T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/482,271 US5789547A (en) 1995-06-07 1995-06-07 Method of producing insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) with correct folding and disulfide bonding
PCT/US1996/008113 WO1996040736A1 (en) 1995-06-07 1996-05-30 Method of producing igf-i and igfbp-3 with correct folding and disulfide bonding

Publications (1)

Publication Number Publication Date
ATE223926T1 true ATE223926T1 (de) 2002-09-15

Family

ID=23915418

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916829T ATE223926T1 (de) 1995-06-07 1996-05-30 Verfahren zur herstellung von igf-1 und igfbp-3 mit richtiger faltung und disulfidbindungen

Country Status (15)

Country Link
US (1) US5789547A (de)
EP (1) EP0832098B1 (de)
JP (1) JPH11507037A (de)
KR (1) KR19990022718A (de)
CN (1) CN1214689A (de)
AT (1) ATE223926T1 (de)
AU (1) AU703489B2 (de)
CA (1) CA2223495A1 (de)
CZ (1) CZ394397A3 (de)
DE (1) DE69623620T2 (de)
DK (1) DK0832098T3 (de)
ES (1) ES2179943T3 (de)
NO (1) NO975749L (de)
PL (1) PL323731A1 (de)
WO (1) WO1996040736A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
US5914390A (en) * 1997-05-12 1999-06-22 Celtrix Pharmaceuticals, Inc. Methods for increasing yields of recombinant proteins
US6653098B1 (en) 1998-02-23 2003-11-25 G. D. Searle & Co. Method of producing mouse and human endostatin
US6436897B2 (en) 1998-06-01 2002-08-20 Celtrix Pharmaceuticals, Inc. Pharmaceutical formulations for IGF/IGFBP
US6417330B1 (en) 1998-06-01 2002-07-09 Celtrix Pharmaceuticals, Inc. Insulin-like growth factor binding protein variants
US20030120042A1 (en) * 2000-03-30 2003-06-26 Takao Yamada Process for producing recombinant protein
US20050033035A1 (en) * 2001-06-07 2005-02-10 Hans-Georg Beisel Mutants of igf binding proteins and methods of production of antagonists thereof
ATE459637T1 (de) * 2004-12-24 2010-03-15 Insmed Inc Gereinigte rhigf-i/rhigfbp-3-komplexe und herstellungsverfahren dafür
US8518877B2 (en) 2007-04-18 2013-08-27 Premacure Ab Method and product for treatment and/or prevention of complications of prematurity
CN109180802A (zh) * 2011-12-15 2019-01-11 爱德迪安（北京）生物技术有限公司 具有降血糖作用的化合物、组合物及其用途
KR20200097679A (ko) 2017-09-11 2020-08-19 샤이어 휴먼 지네틱 테라피즈 인크. 만성 폐 질환 치료를 위한 방법 및 조성물
CN107991492A (zh) * 2017-11-17 2018-05-04 广州赛莱拉干细胞科技股份有限公司 一种胰岛素样生长因子结合蛋白-3的定量检测试剂盒及其非诊断目的的检测方法
CN111876490B (zh) * 2020-07-03 2022-07-15 扬州大学 一种提高猪生长速度的连锁分子标记、其检测方法及应用
ES3005966T3 (en) 2020-10-19 2025-03-17 Oak Hill Bio Ltd Compositions suitable for use in neonates
JP2025502349A (ja) 2022-01-19 2025-01-24 オーク ヒル バイオ リミテッド Ｉｇｆ－１／ｉｇｆｂｐの酸化を低減するための組成物および方法
WO2023139250A1 (en) * 2022-01-24 2023-07-27 Oak Hill Bio Limited Lot release assays for igf‐1/igfbp complexes

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4511503A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511502A (en) * 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) * 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
IL71991A (en) * 1983-06-06 1994-05-30 Genentech Inc Preparation of human FGI and FGE in their processed form through recombinant AND tranology in prokaryotes
US4766205A (en) * 1985-11-13 1988-08-23 Beatrice Companies, Inc. Method for isolation of recombinant polypeptides in biologically active forms
US5258287A (en) * 1988-03-22 1993-11-02 Genentech, Inc. DNA encoding and methods of production of insulin-like growth factor binding protein BP53
US5158875A (en) * 1989-08-25 1992-10-27 Amgen Inc. Production of biologically active insulin-like growth factor i from high expression host cell systems
US5288931A (en) * 1991-12-06 1994-02-22 Genentech, Inc. Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation
AU3812993A (en) * 1992-03-24 1993-10-21 Synergen, Inc. Refolding and purification of insulin-like growth factor I
SE9303784D0 (sv) * 1993-11-16 1993-11-16 Kabi Pharmacia Ab Igf

Also Published As

Publication number Publication date
WO1996040736A1 (en) 1996-12-19
AU703489B2 (en) 1999-03-25
PL323731A1 (en) 1998-04-14
CA2223495A1 (en) 1996-12-19
NO975749L (no) 1998-01-27
KR19990022718A (ko) 1999-03-25
AU5957696A (en) 1996-12-30
CZ394397A3 (cs) 1998-09-16
ES2179943T3 (es) 2003-02-01
DK0832098T3 (da) 2002-12-16
DE69623620D1 (de) 2002-10-17
EP0832098B1 (de) 2002-09-11
NO975749D0 (no) 1997-12-05
CN1214689A (zh) 1999-04-21
EP0832098A4 (de) 1999-09-15
JPH11507037A (ja) 1999-06-22
US5789547A (en) 1998-08-04
EP0832098A1 (de) 1998-04-01
DE69623620T2 (de) 2003-08-07

Similar Documents

Publication Publication Date Title
DE69623620D1 (de) Verfahren zur herstellung von igf-1 und igfbp-3 mit richtiger faltung und disulfidbindungen
ES2058341T3 (es) Subunidades de proteina portadoras de somatomedina humana y proceso para producirlas.
DE59305396D1 (de) Verfahren zur Gewinnung von Proinsulin mit korrekt verbundenen Cystinbrücken
PL323858A1 (en) Compounds and peptides capable to bond to a receptor of erythropoetin
ATE170630T1 (de) Proteine mit geänderten epitopen und verfahren zur deren herstellung
DE69334033D1 (de) Technetium-99M markierte Peptide zur Bilderzeugung von Thrombus
ATE352617T1 (de) Lösliche polypeptidfraktionen des lag-3-proteins; verfahren zur herstellung; therapeutische zusamensetzung; antiidiotypischer antikörper
EP0451194A4 (en) Recombinant dna molecules, hosts, processes and human somatomedin carrier protein-like polypeptides
ATE350053T1 (de) Herstellung von humaninsulin
DE3676683D1 (de) Mischung von derivaten von aminosaeuren, verfahren zur herstellung der mischung und verwendung der mischung zur mengenbestimmung der aminosaeuren.
DE69319012D1 (de) Protein mit Knochenbildungs-Eigenschaften und Verfahren zu seiner Herstellung
DE50208306D1 (de) Verfahren zur Herstellung von nicht-proteinogenen L-Aminosäuren
ATE177459T1 (de) Verfahren zur kontinuierlichen herstellung von flüssigsiliconkautschuken
FI93842B (fi) Menetelmä proteiinien renaturoimiseksi
ATE212360T1 (de) Polyethylenglycol-hirudin-konjugate, deren verfahren zur herstellung und verwendung für die heilung von thrombosen
ATE408631T1 (de) Chimäres protein welches eine intramolekulare chaperon-ähnliche sequenz enthält und dessen anwendung zur insulinproduktion
DE68914221D1 (de) Verfahren zur Herstellung von alifatischen alpha-omega-Diaminen, neue Verbindungen und deren Verwendung für die Haarfärbung.
DE59605774D1 (de) Verfahren zur Herstellung von beta-Carotin-Präparaten mit hohem 9(Z)-Gehalt
ATE171711T1 (de) Cyclohexapeptide und deren mischungen, verfahren zur herstellung sowie deren verwendung
ATE185349T1 (de) Verfahren zur herstellung von dolastatin 15 und deren zwischenprodukten
ATE216778T1 (de) Verfahren zur herstellung von konjugaten aus einem spezifischen bindungspartner und einem kohlenhydrathaltigen protein
ATE332916T1 (de) Farbstoff-markiertes peptid und dessen verwendung zur diagnostik
ATE81013T1 (de) Verfahren zur herstellung von faktor viii:cmangelplasma und ein so erhaltenes mangelplasma.
DE59108261D1 (de) Peptide des HIV-gag Proteins, ihre Herstellung und Verwendung
DE59309978D1 (de) Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0832098

Country of ref document: EP

REN Ceased due to non-payment of the annual fee